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Preoperative radiochemotherapy for locally advanced esophageal cancer
L. Hebrero Jimenez, A. Ramos Trujillo, L. Garcia Sanchez, I. Herruzo Cabrera, A. Slocker Escarpa,
P. Galván Banqueri, J. Villén Villén
Complejo Hospitalario Carlos Haya, Oncología Radioterápica, Spain
Introduction.Although surgery is a keystoneof care inpatients (p)with advancedesophageal, 3 yearOSwith this treatment remains
poor. In an attempt to improve these results numerous studies using preoperative radiochemotherapy have been performed.
They have shown that neoadjuvant therapy decreases the incidence of micrometastasis, and increases both resectability and
the number of pathologic complete responses.
Aim.We aimed to evaluate the efﬁcacy of neoadjuvant radiochemotherapy in a series of patientswith locally advanced esophageal
cancer treated at our institution.
Methods and study design. We analyzed 23 p with esophageal cancer stage T2-T4/N0-1 (ultrasound scan and CT) treated with EBRT
(45Gy/25 fractions) and concomitant cisplatin and 5-FU. Oncological surgery (esophagectomy) was performed in eligible patients
6–7 weeks after chemoradiation. DEVELOPMENT: between January 2000 and December 2012, a total of 23 p (21 men and 2 women)
with a median age of 63 (range 38–76) were treated for esophageal cancer. Tumor locations: 15 p middle third and 9 p distal third.
Clinical Stage: cT2 (1 p), cT3 (19 p), cT4 (3 p), cN+ (11 p) and cN0 (12 p). Histology: Adenocarcinoma (9) and epidermoid carcinoma
(14) Surgery consisted in a complete esophagectomy in 19 p; 1 p subtotal esophagectomy, and 3 p were not eligible for surgery
due to inoperabiliy criteria.
Results. “Downstaging” was achieved in 18 p (78.3%), with pathologic complete response in 7 p (30.4%). With a median follow-up
of 21.4 months (range 4–122), 12 p are alive free of disease, and 11 p death (7 tumor-related mortality). No toxicity grade III-IV
was recorded.
Conclusions. Preoperative radiochemotherapy should be considered in patients with locally advanced esophageal cancer, as it can
improve local control with a manageable toxicity proﬁle.
http://dx.doi.org/10.1016/j.rpor.2013.03.210
Preoperative radiochemotherapy of rectal cancer: Retrospective study of cases reports
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Objective. Description of epidemiological data, treatment tolerance, acute toxicity of radiotherapy and pathological response
obtained, the 5-year overall survival and the 5-year disease free survival in patients diagnosed of rectal cancer treated with
preoperative radiochemotherapy.
Methods. Epidemiologic, observational, descriptive, retrospective study of cases reports. The study has been to apply the inclusion
and exclusion criteria for a population of 177 patients, eventually obtaining a sample of 60 patients. The next step was to sys-
tematically review of their clinical stories. Patients were treated with preoperative radiotherapy (with or without chemotherapy)
at the University General Hospital of Albacete (Spain) from March 2002 till March 2008 (both months included).
Main results. 31.7% of patients were women and 68.3% men. Mean age 65.53 years (age range: 26–82 years). 100% of patients
completed treatment with radiotherapy. Tolerance to treatment was excellent according to RTOG scale. The chemotherapy there
was various schemes, such as 5-FU and capecitabine orally, especially in the last years. All the patients had surgery and the
histological report showed tumoral regresion ranging between 1 and 5. The median follow-up period was 5.45 years (range,
0.77–8.78 years). The 2-year overall survival rates were 93.3%. The 5-year overall survival rates were 68%. The 2-year disease free
survival rates were 78.3%. The 5-year disease free survival rates were 66.2%.
Conclusions. The sex and the age resemble the national epidemiological data. Preoperative radiochemotherapy on patients diag-
nosed of rectal cancer is an adequate treatment since it gets good results and good tolerance. The overall survival rates and
disease free survival rates at 2 and 5 years, were similar to other studies.
http://dx.doi.org/10.1016/j.rpor.2013.03.211
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Introduction. The standard treatment of rectal cancers (RCA) is neoadjuvant radio-chemotherapy plus mesorectal surgery (MRS.
In our hospital a national initiative called VIKING PROJECT (VP) was introduced in order to achieve a high quality standard of
care.
Purpose. To compare the outcomes of pts with RCA prospectively included in the VP against a cohort of standard pts (SP) referred
for radiotherapy but staged and operated in others hospitals where VP is not introduced.
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Materials and method. We analyze 133 patients staged IIa–IIIc. 59 pts in VP, 74 pts in SP. Groups were well balanced. There were
less stages II (9% vs. 29%) and stages III (34% VS. 35%) in VP than in SP p<0.0001. All pts were treated to a total dose of 50.4Gy and
concomitant ﬂuoropyrimidine-based chemotherapy. A dedicated colorectal team of surgeons underwent all MRS in our hospital.
We analyze pts for overall survival (OS) and disease free survival (DFS).
Results. Median follow up was 3.25 years (0.25–9.28) OS at 2 and 5 years: 82%, 74%. OS cancer-speciﬁc (CA) at 2 and 5 years: 90%,
78%. Mean DFS global was: 7.05 years (IC 95%: 6.31–7.79). Mean DFS local relapse was: 8.17 years (IC 95: 7.59–8.75). Mean OS VP
vs. SP was 3.68 vs. 7.34 years hazard ratio (HR) = 1.068, p=ns. OS (CA) VP vs. SP 3.9 vs. 7.9 years, HR=1.07, p=ns. Mean DFS VP
vs. SP 3.7 vs. 6.83, HR=1.49, p=ns. Mean DFS (local relapse) VP vs. SP 3.88 vs. 8.08 years HR=1.26, p=ns. Pts whose pathological
stage was higher (PG) than clinical stage had worse OS survival than those with non-response (NR) or any response (AR): PG=5.14
years vs. NR=6.2 vs. AR=7.55, p<0.05.
Conclusion. Patients included in VP suffer from more advanced disease than PS, yet their OS and DFS were equivalent.
http://dx.doi.org/10.1016/j.rpor.2013.03.212
Preoperative treatment radiochemotherapy RTCT schemewith carbo-paclitaxel weekly radiosensitizing of locally
advanced esophageal carcinoma. Initial results in the Hospital Universitario Virgen Arrixaca Unit esophagus
gastric cancer treatment
M. Porras Martinez
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Introduction and objectives. In 2011, following the preliminary results of the CROSS trial, published in late 2010 our unit esopha-
gogastric cancer treatment decided to start with this promising protocol. In our case we intend to ﬁnd out if you may get better
results than the previous protocol used in our center RTCT including cisplatin and 5FU-in 2nd place if possible with a lower
mortality.
Material and methods. We included 10 patients where it has established the possibility of preoperative treatment as inclusion
exclusion criteria of the protocol, respecting the guidelines of dose and schedule recommended.
Results. The 50% of patients had TNM stage, T3N1M0 while the remaining 50% were T3N0M0. The predominant histology was
adenocarcinoma of the lower esophageous-cardia in 90%.Mean agewas 58 years (range 35–75 years) 90% of the patients improved
from the dysphagia symptoms, not requiring entrance feeding tube or in any case admittance at hospital. Surgery was performed
at 6 weeks CTRT ﬁnish. Presented a low rate of complications: only 1 patient (10%) had wound dehiscence. Another patient
had hypoxemia secondary to bilateral basal atelectasis (10%). 0% mortality. In 100% of patients after CTRT understaging was
objectiﬁed. The majority of patients had R0 resection. And pathological stage. Most frequent was yPT1a-bN0M0 The results in
terms of survival are not mature
Conclusions. In principle it is a secure protocol agile and very effective, facilitating surgery with level low morbidity associated.
http://dx.doi.org/10.1016/j.rpor.2013.03.213
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Objective. A signiﬁcant decrease in lymph node yield after preoperative radio-chemotherapy for rectal cancer compared with
surgery upfront has been described. The goal of this investigation is to determine the prognostic value of the number of lymph
nodes retrieved in patients with LARC treated with preoperative RCT. We also investigated the prognostic value of the local and
regional response after RCT.
Material and methods. Eligible patients presented a diagnosis of proven rectal Adenocarcinoma, stage T2 to T4 and/or N1 to N2.
Patients were treated with pelvic RT (46–50Gy in 2Gy fractions), and 5Fu iv in continuous infusion (225mg/m2) or Capecitabine
(825mg/m2) during RT, followed by TME in 6 weeks after RT-CT. Number of nodes retrieved was analyzed and association with
clinicopathological characteristics were studied. Univariant and multivariant survival analysis were performed.
Results. The mean number of nodes identiﬁed in the surgical specimen was 10 with a range from 0 to 28. 23% of the patients had
at least 7 nodes retrieved, 50% of the patients had at least 10 nodes, 35% at least 12 nodes and 24% at least 14 nodes retrieved. A
signiﬁcant correlation (p=0.001) was found between the number of lymph nodes retrieved and number of lymph nodes affected
(Pearson coefﬁcient 0.37). Retrieval of at least 10 lymph nodes and yT response were independent prognostic factors (p=0.03 and
p=0.005 respectively).
